Shanxi Jinbo Bio-Pharmaceutical920982.BJValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Shanxi Jinbo Bio-Pharmaceutical (920982.BJ) trades at a P/E of 27.40x, P/B of 7.30x, P/S of 9.63x, and a dividend yield of 1.16%.
Longitudinal percentile comparison: P/E sits at the 15th percentile over the trailing 10Y window (vs. 16th percentile over 3Y); P/B sits at the 9th percentile over the trailing 10Y window (vs. 10th percentile over 3Y); P/S sits at the 8th percentile over the trailing 10Y window (vs. 9th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 45th percentile within its industry and the 38th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.16%, ranking at the 86th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 5.5 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Shanxi Jinbo Bio-Pharmaceutical operates in the — sector. Data refreshes weekly and is for reference only, not investment advice.
Want the full picture on whether Shanxi Jinbo Bio-Pharmaceutical (920982.BJ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 27.40 | ||||||
| P/B (MRQ) | 7.30 | ||||||
| P/S (TTM) | 9.63 | ||||||
| Dividend Yield | 1.16% | ||||||
| Buyback + Div Yield | 1.16% |